Signati Medical Inc. has introduced a groundbreaking innovation in the treatment of varicose veins, addressing longstanding limitations of existing procedures. This novel method combines precision, efficiency, and minimally invasive technology to occlude and divide veins, vessels, or ducts with fewer complications and enhanced patient outcomes.

Traditional treatments for varicose veins—ranging from sclerotherapy to invasive surgery—often come with drawbacks such as recurrence, nerve damage, and extended recovery times. Signati Medical Inc.’s patented approach leverages a bipolar coagulating device and a surgical clamp to efficiently isolate, coagulate, and separate targeted veins. By integrating advanced coagulation technology, this method effectively seals veins while minimizing scarring, reducing procedural complexity, and mitigating risks associated with conventional techniques.

A key aspect of this invention is its ability to deliver precise occlusion and division without necessitating sharp instruments, significantly lowering the risk of clinician exposure to bodily fluids. Additionally, the approach eliminates the need for highly specialized surgical skills, making it more accessible across a broader range of clinical settings. With a focus on reducing post-operative pain and complications, this method also aims to prevent spontaneous vein regeneration, a common issue with traditional varicose vein treatments.

The technology’s versatility extends beyond varicose veins, offering potential applications in vasectomy procedures and other vascular interventions. As the demand for safer, more effective vein treatments grows, Signati Medical Inc. is leading the way with an innovation that redefines efficiency and patient care in vascular medicine. This advancement not only streamlines treatment but also paves the way for a future where vein disorders can be managed with greater ease and precision.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.